Pepteca

Growth hormone axis

CJC-1295

with DAC · Modified GRF (1-29) · GHRH · analog

A growth-hormone-releasing hormone analog usually stacked with Ipamorelin — early human pharmacology, research-only status.

Reference status

Editorial research · independent review pending · 3 claims graded

Editorial researchResearch-onlyEmerging · early human66% positive discussion

What it is

CJC-1295 is a synthetic analog of GHRH designed to extend how long it stimulates GH release. The 'DAC' version has a much longer half-life. It is the classic partner to Ipamorelin in GH stacks.

Small human studies show it increases GH and IGF-1 levels. As with the other GH-axis peptides, the leap from 'raises a hormone' to 'delivers the marketed physique/longevity benefits safely' is not backed by strong trials.

The science, graded

What’s claimed — and how strong the evidence behind each claim actually is.

“Increases GH and IGF-1 levels”

Small human studies support the endocrine effect.

Claim-level citation mapping is in progress.

emerging
Emerging · early human

“Improves muscle, fat loss and recovery”

Community-reported; not demonstrated in controlled outcome trials.

Claim-level citation mapping is in progress.

anecdotal
Anecdotal · community

“Safe for long-term continuous use”

Long-term safety of elevating GH/IGF-1 chronically is not established.

Claim-level citation mapping is in progress.

hype
Hype · unproven

Legal and regulatory context

Separate summaries for Great Britain, the United States, and the European Union. These are preliminary research summaries awaiting independent regional review; they are not legal determinations or advice.

Great Britain

Preliminary researchResearch-only

Research-only in the UK; not licensed for human use and prohibited in sport under WADA.

This is preliminary regulatory research, not a reviewed legal determination or legal advice.

United States

Preliminary researchReview pending

Regional legal and regulatory review required before publication.

This is preliminary regulatory research, not a reviewed legal determination or legal advice.

European Union

Preliminary researchReview pending

Regional legal and regulatory review required before publication.

This is preliminary regulatory research, not a reviewed legal determination or legal advice.

What the community says

Almost always discussed as one half of 'CJC + Ipamorelin'. Debate centres on DAC vs no-DAC and injection frequency.

Share of positive discussion66%

Where they’re talking

  • r/PeptidesDosing-protocol threads dominate.
  • ForumsDAC half-life debates.

Appears in these stacks

CJC-1295 + Ipamorelin

Growth-hormone axis support

The classic growth-hormone secretagogue pairing: a GHRH analog plus a selective GH secretagogue, used to raise GH pulsatility. Endocrine effect is fairly supported; the downstream physique benefits are anecdotal.

References

  1. 1.Supply unlicensed medicinal products (specials) · MHRA
  2. 2.FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
  3. 3.Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks · U.S. Food and Drug Administration
  4. 4.Buying medicines online · European Medicines Agency
Educational, not advice or endorsement. Educational reference only. Independent review is pending. Do not use this entry to make medical, purchasing, dosing, or treatment decisions.This editorial research entry preserves the existing material but has not yet passed independent scientific and regional regulatory review.